Eli Lilly and Company (BVMF:LILY34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 5.30T +45.4% |
| Revenue (ttm) | 412.73B +49.6% |
| Net Income | 138.38B +93.6% |
| EPS | 154.33 +94.8% |
| Shares Out | n/a |
| PE Ratio | 38.28 |
| Forward PE | 29.13 |
| Dividend | 0.77 (0.39%) |
| Ex-Dividend Date | Aug 13, 2026 |
| Volume | 10,611 |
| Open | 198.69 |
| Previous Close | 197.37 |
| Day's Range | 196.02 - 198.69 |
| 52-Week Range | 126.72 - 223.07 |
| Beta | 0.50 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Patients are suing GLP-1 drugmakers over the risk of sudden vision loss. The little-discussed potential risk of popular diabetes and weight-loss drugs is on warning labels outside of the U.S.
Michelle Fennell was sitting at her desk when her right eye started feeling heavy. Suddenly, it was blurry and her peripheral vision waned. It felt like she was looking through a fishbowl, she could s...
US FDA approves Lilly's breast cancer drug combo
The US FDA has approved Eli Lilly's drug combination to treat adults with a type of advanced breast cancer that has spread to other parts of the body, the drugmaker said on Friday.
U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
Inluriyo plus Verzenio delivers proven clinical benefit after the evidence-based practice of maximizing initial treatment with an aromatase inhibitor, with or without a CDK4/6 inhibitor In the Phase ...
40% of U.S. Adults to Use GLP-1s? Raul Shah on LLY, NVO & Weight Loss "Mania"
Raul Shah (@Raul_DSF) is very bullish on the future of GLP-1s due to accelerating demand trends generating a "mania" effect in the market. He points to the superiority Eli Lilly (LLY) has demonstrated...
Tuesday's First Moves: LLY & ETSY Upgrades, PLAY Plunges After Earnings
More and more, Eli Lilly (LLY) is being seen as the winner in the GLP-1 race over Novo (NVO), with Berenberg backing that thesis in its upgrade on the stock. Diane King Hall explains what the analyst ...
Options Corner: LLY Upgrade Injects Bullish Stock Momentum
Berenberg upgraded Eli Lilly (LLY) to buy from hold and boosted its price target to $1,400 from $1,220 as the healthcare giant extends its lead over Novo (NVO). Rick Ducat stacks the stock against its...
Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health
Pivotal results from TRIUMPH-2 showed retatrutide, an investigational triple hormone receptor agonist, delivered substantial weight loss and A1C improvements in obesity and type 2 diabetes Findings fr...
Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs
Eli Lilly on Monday said it has captured more than 30% of new patients in the U.S. market for oral obesity treatments, narrowing the early lead gained by Danish rival Novo Nordisk with its Wegovy pi...
Eli Lilly and Company Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
A broad obesity portfolio is being developed to address diverse patient needs, with foundational and new therapies expanding access and improving outcomes. Cost-effectiveness data and digital initiatives are driving employer engagement and consumer orientation, while international launches and pipeline assets support growth.
People are taking bootleg versions of an Eli Lilly drug that isn't approved yet. Ohio wants it to stop.
As bootleg versions of an experimental drug from Eli Lilly flood the market, regulators are trying to curb supply.
Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
INDIANAPOLIS, Sept. 11, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of AtaiBeckley Inc. AtaiBeckley is a clinical-stage biopharm...
10% Move Ahead? Ross Gerber Reveals What He's Buying Now
Ross Gerber, CEO, Gerber Kawasaki lays out the path to a potential 10% move higher — and lays out the stocks he says still deserve capital even in a choppy market.
Cholesterol drug setback casts doubt over multibillion-dollar race
Novartis' pelacarsen failed to reduce cardiovascular events despite lowering the harmful cholesterol Lp(a). The setback raises uncertainty for rival experimental Lp(a) drugs from Amgen and Eli Lilly.
Plastic surgery is booming with boomers. Here's how to cash in on the antiaging craze.
Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.
Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense
Drugmakers are getting a boost from strong earnings and M&A. But they're also havens in a rocky market.
Aspen sees Mounjaro Africa sales above $124 million in 2027
Aspen Pharmacare expects African sales of Eli Lilly's blockbuster weight-loss and diabetes drug Mounjaro to exceed 2 billion rand ($124 million) in its current financial year, buoyed by surging deman...
Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference
INDIANAPOLIS, Sept. 1, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026.
GLP-1 weight loss drugs effective even at low starter doses
People taking popular GLP-1 obesity drugs who remain on low starter doses will lose some weight but may still experience side effects, although significantly less nausea than those who graduate to h...
600,000 seniors have signed up for obesity drugs under new Medicare program
U.S. Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz said on Monday that 600,000 seniors have signed up to receive GLP-1 weight loss medications in the first two months o...
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
Nearly a dozen drugmakers are reportedly slated to voluntarily sell their medications at lower prices under deals expected to be announced by President Donald Trump on Monday. The string of deals buil...
Trump administration to announce drug pricing deals
U.S. President Donald Trump is expected to announce a new round of drug-pricing agreements on Monday, a White House official said, part of a push to make healthcare more affordable for Americans.
Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What It Means for the Stock.
Eli Lilly agrees to acquire Merida Biosciences, the developer of autoimmune drugs, marking the latest move to bolster its portfolio through strategic acquisitions.
Eli Lilly to Buy Merida Biosciences For Up to $2.875 Billion
Eli Lilly has agreed to pay up to $2.875 billion in cash for biotechnology company Merida Biosciences in a deal that bolsters the drugmaker's immunology portfolio.
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
At Week 52, Taltz and Zepbound maintained or further improved psoriasis or psoriatic arthritis disease activity from Week 36, when statistically superior improvements versus Taltz alone were observed ...